Physician profile
Todd Heimowitz
NPI 1972761567
$4,692.19
in general payments reported to CMS, 2019-2025
26 companies · $1,667 in 2025
The $1,667 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $375 · 2021: $531 · 2022: $549 · 2023: $375 · 2024: $669 · 2025: $1,667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,710.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,539.10 | 2021-2025 | Ffrangio, Onyx Frontier, Symplicity G3 |
| Shockwave Medical, INC | $1,091.05 | 2019-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novartis Pharmaceuticals Corporation | $240.90 | 2019-2025 | |
| Boston Scientific Corporation | $210.16 | 2019-2025 | Watchman Flx |
| Pfizer INC. | $200.70 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $187.90 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $181.06 | 2019-2025 | Wainua |
| Abbott Laboratories | $171.21 | 2021-2025 | Optis |
| Abiomed | $145.51 | 2019 | |
| Amgen INC. | $117.27 | 2019-2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $99.14 | 2019-2025 | Eliquis, Camzyos |
| Medicomp INC | $88.45 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $62.95 | 2019-2021 | |
| Edwards Lifesciences Corporation | $49.74 | 2023 | |
| Lilly USA, LLC | $45.22 | 2025 | Jardiance, Mounjaro, Zepbound |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $38.63 | 2025 | Wegovy, Ozempic, Rybelsus |
| Alnylam Pharmaceuticals INC. | $37.95 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $36.23 | 2019 | |
| Impulse Dynamics (USA) INC. | $22.77 | 2025 | Optimizer |
| Abbvie INC. | $20.91 | 2025 | |
| Esperion Therapeutics, INC. | $19.73 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.38 | 2025 | |
| Exact Sciences Corporation | $18.85 | 2024 | Cologuard Collection Kit |
| Chiesi USA, INC. | $16.18 | 2020 | |
| Arbor Pharmaceuticals, INC. | $15.90 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Heimowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.